Cure Parkinson’s is a major supporter of clinical trials for disease modification in Parkinson’s. For a new therapy to be approved for use in hospitals, it must first pass through three phases of clinical testing.

Phase 1 is a small, short test of safety involving both healthy volunteers and individuals with a particular disease. Phase 2 is a larger and longer test of safety in a disease of interest with additional measures looking for evidence of efficacy. Phase 3 is a very large, multi-year study to determine efficacy and safety of a new therapy for long-term use.

Cure Parkinsons has many clinical trials underway across these different phases of clinical development. The drugs listed below are part of the clinical trials being progressed under our International Linked Clinical Trials programme (iLCT). There are now over 30 drugs already in clinical use that have been prioritised by the iLCT committee for Parkinson’s with 17 drugs already in, or about to go into, clinical trials.

The Phase 3 International Linked Clinical Trials

Exenatide

Exenatide (also known as Bydureon) is a clinically available and widely used drug for the treatment of type 2 diabetes. Cure Parkinson’s is investigating the repurposing of exenatide for Parkinson’s.

Exenatide and Parkinson’s
Ambroxol

Ambroxol is used to treat respiratory conditions. Cure Parkinson’s has supported a phase ll repurposing trial and is supporting a further phase III clinical trial which is being designed to test the efficacy of ambroxol in slowing the progression of Parkinson’s.

Ambroxol and Parkinson’s

Clinical trials recruiting now

Find out more

The Phase 2 International Linked Clinical Trials

The ‘ADepT-PD Study’ – Nortriptyline and Parkinson’s (recruiting now)

There is now a large nationwide study being conducted in the UK, supported by Cure Parkinson’s, evaluating whether the widely used anti-depressant, nortriptyline, can influence the course of Parkinson’s progression.

Read more about nortriptyline and Parkinson’s and the ADepT-PD trial

The ‘AZA-PD Study’ – Azathioprine and Parkinson’s (recruiting now)

This medication is already in use as a treatment for inflammation and the AZA-PD Study is looking at dampening down the immune response as a way of slowing the progression of Parkinson’s. The trial is being conducted in Cambridge (UK) and is supported by Cure Parkinson’s.

Read more about Azathioprine and Parkinson’s

The Anle138b Phase 1b Study (recruiting now)

Anle138b is a promising drug that targets the toxic accumulation of alpha-synuclein with the aim of alleviating neurodegenerative symptoms. This study is now recruiting people with Parkinson’s to participate.

Find out more here.

The ‘PROSEEK Study’ – vodobatinib (KO706) in Parkinson’s (recruiting now)

Vodobatinib – previously known as KO706 – is very similar to a drug called nilotinib (a c-Abl inhibitor), also supported into trial by Cure Parkinson’s, but vodobatinib has been designed to better access the brain.

Read more about c-Abl inhibitors

Read more about the PROSEEK Trial

The ‘NLY-01’ Trial (recruiting now)

A similar drug to exenatide, this drug is designed to access the brain better – NLY-01 was highly prioritised by the International Linked Clinical Trials (iLCT) committee in 2017. Similar drugs to NLY-01 already approved for the treatment of type 2 diabetes include exenatide, lixisenatide, and liraglutide – all three of these drugs have been or are being trialled in Parkinson’s through the Cure Parkinson’s iLCT programme. We are delighted to see Neuraly move this drug into a phase 2 clinical trial in the U.S.

Find out more here.

The ‘UP-Study’ – UDCA and Parkinson’s (recruitment complete)

This drug is used in the treatment of gallstones and has been determined to have beneficial effects on mitochondrial function in models of Parkinson’s. The UP study – UDCA in Parkinson’s, supported by Cure Parkinson’s and conducted in Sheffield and London (UK), has now finished and we are awaiting results.

Read more about UDCA and Parkinson’s

The ‘FAIR-PARK Study’ – Deferiprone and Parkinson’s (recruitment complete)

Deferiprone is an iron chelator – a class of medication used to reduce iron levels in the body. There is evidence that reducing iron in the brain can be beneficial for Parkinson’s.

Read more about Deferiprone and Parkinson’s

Liraglutide and lixisenatide in Parkinson’s (recruitment complete)

Like exenatide, liraglutide and lixisenatide are part of a group of drugs called GLP-1R agonists, used to treat type 2 diabetes. Cure Parkinson’s is supporting these trials to determine their impact of the progression of Parkinson’s.

Read more about the liraglutide trial here

Read more about the lixisenatide trial here

The APM Trials – Australian Parkinson’s Mission

The Australian Parkinson’s Mission (APM) is a 5-year clinical trial project funded by the Australian Federal Government. The first trial is testing three drugs that have been prioritised by the International Linked Clinical Trials initiative, comparing them with a single placebo. Further APM trials are being set up.

Read more about the APM